• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Addition of bevacizumab fails to benefit overall survival in newly diagnosed glioblastoma [RTOG 0825 trial]

byHayley Walker, MDandXu Gao
February 23, 2014
in Chronic Disease, Neurology, Oncology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

Image: PD 

1. When added after initial treatment with temozolomide and radiotherapy, bevacizumab did not improve overall survival in newly diagnosed glioblastoma. 

2. Although bevacizumab improved progression-free survival, it was associated with greater deterioration in neurocognitive function and symptom severity.

Evidence Rating Level: 1 (Excellent)     

Study Rundown: Treatment with bevacizumab, an antibody against vascular endothelial growth factor A (VEGF-A), has produced dramatic responses on magnetic resonance imaging (MRI) in patients with recurrent glioblastoma. However, the clinical benefit of bevacizumab has been called into question; there is concern that imaging responses reflect vascular stabilization by bevacizumab rather than tumor regression. This study compared bevacizumab to placebo in patients receiving standard therapy (radiotherapy plus temozolomide) for newly diagnosed glioblastoma.

While bevacizumab did not improve overall survival compared to placebo, it did improve progression free survival. However, of patients deemed progression-free on imaging, patients receiving bevacizumab reported greater declines in perceived cognitive ability and also received worse scores on objective measures of neurocognitive function. Future studies and analyses are needed to clarify the relationship between improved progression free survival, as measured by imaging, and patients’ outcomes and wellbeing. Despite concerns about bevacizumab, it is important to carefully study any potentially beneficial therapies for this devastating disease with few available treatment options.

Click to read the study in the NEJM

RELATED REPORTS

Addition of atezolizumab to capecitabine + bevacizumab is not clinically beneficial in the treatment of refractory metastatic colorectal cancer

Biosimilar drugs undergo rigorous clinical testing and yield comparable outcomes to biologics

Pembrolizumab improves survival outcomes in cervical cancer patients

Click to read an accompanying editorial in the NEJM

Relevant Reading: Bevacizumab plus Radiotherapy–Temozolomide for Newly Diagnosed Glioblastoma

In-Depth [randomized, double-blind, placebo-controlled trial]: In this study, 637 patients being treated for glioblastoma with radiotherapy and temozolomide were randomized to receive either bevacizumab or placebo beginning during week 4 of radiotherapy. At disease progression, treatment group was revealed; patients could then be initiated or continued on bevacizumab. Primary end points were duration of overall survival and progression-free survival. A substudy of subjects without tumor progression on imaging examined patient-reported outcomes (e.g. symptom severity) and neurocognitive functioning in the bevacizumab and placebo groups.

Median overall survival was 15.7 months in the bevacizumab group and 16.1 months in the placebo group (HR for death in bevacizumab group 1.13, 95% CI 0.93 to 1.37; p=0.21). Median progression free survival was 10.7 months in the bevacizumab group and 7.3 months in the placebo group (HR for progression or death 0.79, 95% CI 0.66 to 0.94, p=0.007). Among patients deemed progression-free, those in the bevacizumab group experienced greater reductions in scores of cognitive function and perceived greater deterioration in symptom severity than those in the control group. Several side effects were more common in the bevacizumab group than the placebo group; these include serious neutropenia and thrombocytopenia, hypertension, thromboembolic disease, visceral perforation, and serious hemorrhage.

©2012-2014 2minutemedicine.com. All rights reserved. No works may be reproduced without expressed written consent from 2minutemedicine.com. Disclaimer: We present factual information directly from peer reviewed medical journals. No post should be construed as medical advice and is not intended as such by the authors, editors, staff or by 2minutemedicine.com. PLEASE SEE A HEALTHCARE PROVIDER IN YOUR AREA IF YOU SEEK MEDICAL ADVICE OF ANY SORT.  

Tags: bevacizumabglioblastoma
Previous Post

Video-based behavioral intervention benefits clinical skin examinations

Next Post

First line bevacizumab fails to improve survival newly diagnosed glioblastoma patients [AVAglio trial]

RelatedReports

Noninvasive imaging method detects and evaluates size of metastases
Chronic Disease

Addition of atezolizumab to capecitabine + bevacizumab is not clinically beneficial in the treatment of refractory metastatic colorectal cancer

February 25, 2022
Quick Take: Effect of Pregabalin on Radiotherapy-Related Neuropathic Pain in Patients With Head and Neck Cancer: A Randomized Controlled Trial
Oncology

Biosimilar drugs undergo rigorous clinical testing and yield comparable outcomes to biologics

February 22, 2022
Cervical cancer screening practices less cost-effective than suggested guidelines
Obstetrics

Pembrolizumab improves survival outcomes in cervical cancer patients

February 15, 2022
#VisualAbstract: Endocrine therapy plus oral S-1 improves invasive  disease-free survival in patients with ER⁺ breast cancer
StudyGraphics

#VisualAbstract: BRAF/MEK inhibitor therapy may be associated with risk of uveitis in patients with advanced melanoma

February 11, 2021
Next Post
Pre-operative transcranial magnetic stimulation useful for language mapping

First line bevacizumab fails to improve survival newly diagnosed glioblastoma patients [AVAglio trial]

Classics Series, Landmark Trials in Medicine

CT scans associated with increased risk of malignancy [Pediatrics Classics Series]

Rituximab noninferior to conventional therapy in ANCA-associated vasculitis: RAVE Trial

2 Minute Medicine Rewind February 17 – February 23, 2014

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Stereotactic body radiotherapy as a state of the art treatment option in inoperable non-small cell lung cancer [Classics Series]
  • Health system-based care associated with better treatment use and high rates of tobacco abstinence at 3 months post-discharge in hospitalized smokers
  • APOEε4 genotype may increase risk of chronic traumatic encephalopathy following repetitive head impact
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.